Rxsight Inc (RXST) Stock Price, Quote & News

Company Profile

RxSight, Inc., a commercial-stage medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight Light Adjustable Lens (LAL), an intraocular lens made of photosensitive material that changes shape in response...

Industry: Medical Devices

Sector: Healthcare

Phone: 949 521 7830

Website: www.rxsight.com

Address:

100 Columbia, Aliso Viejo, United States

Bullishcatalyst Nov. 13 at 8:15 PM

$RXST run from this turd

0 · Reply

BillionerOfKing Nov. 13 at 5:31 AM

$RXST Current Stock Price: $10.00 Contracts to trade: $10 RXST Nov 21 2025 Call Entry: $0.54 Exit: $0.75 ROI: 39% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts

0 · Reply

nathan_ross88 Nov. 12 at 11:41 AM

$RXST medtech growth. Over base top, +7–10% room. Watch revenue cadence commentary

0 · Reply

Vaprtrl Nov. 10 at 7:06 PM

$RXST I smell $12 coming soon

0 · Reply

RocketThief Nov. 7 at 3:26 PM

$RXST that report was solid. Will be happy/greedy if the opportunity to buy $7S comes again

0 · Reply

Vaprtrl Nov. 7 at 6:44 AM

$RXST let’s fill these gaps!

0 · Reply

JarvisFlow Nov. 6 at 10:03 PM

JP Morgan has adjusted their stance on RxSight ( $RXST ), setting the rating to Underweight with a target price of 8 → 9.

0 · Reply

BryGuy29 Nov. 6 at 6:41 PM

$RXST Just sell the company already….. we all know it’s bound to happen.

0 · Reply

JarvisFlow Nov. 6 at 3:43 PM

Wells Fargo updates rating for RxSight ( $RXST ) to Equal-Weight, target set at 9 → 10.

0 · Reply

No_Body_Knows Nov. 6 at 1:51 PM

$RXST

1 · Reply

RxSight, Inc. (RXST) Q3 2025 Earnings Call Transcript

Nov 5, 2025, 4:05 PM EST - 11 days ago

RxSight, Inc. Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 4:05 PM EDT - 25 days ago

RxSight, Inc. to Report Third Quarter 2025 Financial Results on November 5, 2025

Oct 16, 2025, 4:05 PM EDT - 4 weeks ago

RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting

Sep 22, 2025, 8:49 AM EDT - 7 weeks ago

The Bottom Fishing Club - RxSight: A Ski-Jump Reversal Pattern?

Sep 22, 2025, 4:24 AM EDT - 7 weeks ago

RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - RXST

Sep 21, 2025, 7:22 AM EDT - 2 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight

Sep 16, 2025, 5:06 PM EDT - 2 months ago

DEADLINE NEXT WEEK: Berger Montague Advises RxSight, Inc. (NASDAQ: RXST) Investors to Contact the Firm Before September 22, 2025

Sep 14, 2025, 7:17 AM EDT - 2 months ago

RXST STOCK NEWS: RxSight, Inc. Investors Urged to Act by September 22 Court Deadline -- Contact BFA Law if You Suffered Losses

Sep 12, 2025, 8:18 AM EDT - 2 months ago

RXST SECURITIES NOTICE: Did RxSight, Inc. Mislead Investors? Contact BFA Law if You Lost Money on Your Investment

Sep 8, 2025, 1:01 PM EDT - 2 months ago

RxSight, Inc. (RXST) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Sep 6, 2025, 9:00 AM EDT - 2 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight

Sep 6, 2025, 7:18 AM EDT - 2 months ago

RXST LAWSUIT NOTICE: Lose Money on RxSight, Inc.? Contact BFA Law Prior to September 22 Legal Deadline (NASDAQ:RXST)

Sep 4, 2025, 8:45 AM EDT - 2 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 22, 2025 in RxSight, Inc. Lawsuit - RXST

Aug 29, 2025, 7:07 AM EDT - 2 months ago

RXST SHAREHOLDERS: RxSight, Inc. Investors may have been Affected by Fraud – Contact BFA Law by September 22 Court Deadline (NASDAQ:RXST)

Aug 25, 2025, 4:05 PM EDT - 2 months ago

RxSight, Inc. to Present at the Morgan Stanley Healthcare Conference

Aug 23, 2025, 7:08 AM EDT - 3 months ago

RXST CLASS REMINDER: Suffer Losses on Your RxSight, Inc. Investment? Contact BFA Law before the September 22 Court Deadline (NASDAQ:RXST)

Aug 22, 2025, 10:25 AM EDT - 3 months ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RxSight

Aug 21, 2025, 7:05 AM EDT - 3 months ago

Shareholders who lost money on their RxSight, Inc. (NASDAQ: RXST) Investment Should Contact Wolf Haldenstein Immediately as the Lead Plaintiff Deadline is September 22nd

Aug 13, 2025, 8:33 AM EDT - 3 months ago

RXSIGHT STOCK: Lose Money on Your RxSight, Inc. (NASDAQ:RXST) Investment? Contact BFA Law before the September 22 Legal Deadline

Aug 11, 2025, 8:18 AM EDT - 3 months ago

RXST COURT NOTICE: RxSight, Inc. Investors may have been Affected by Fraud -- Contact BFA Law before September 22 if You Suffered Losses (NASDAQ:RXST)

Aug 8, 2025, 2:29 PM EDT - 3 months ago

RxSight, Inc. (RXST) Q2 2025 Earnings Call Transcript

Aug 7, 2025, 4:05 PM EDT - 3 months ago

RxSight, Inc. Reports Second Quarter 2025 Financial Results

Aug 4, 2025, 8:05 AM EDT - 3 months ago

RxSight, Inc. Appoints Raymond W. Cohen to Its Board of Directors

Jul 30, 2025, 8:36 AM EDT - 3 months ago

RXST INVESTORS: RxSight, Inc. (NASDAQ:RXST) Investors may have been Affected by Fraud – Contact BFA Law by September 22 about Potentially Recovering Losses

Jul 28, 2025, 8:36 AM EDT - 3 months ago

RXST LAWSUIT: RxSight, Inc. Sued for Fraud after LDD Sales Plummet – Contact BFA Law by September 22 Court Deadline (NASDAQ:RXST)

Jul 25, 2025, 2:26 PM EDT - 4 months ago

Berger Montague PC Investigates Securities Claims Against RxSight, Inc. (NASDAQ: RXST)

Jul 23, 2025, 4:56 PM EDT - 4 months ago

RxSight, Inc. Investors: Company Investigated by the Portnoy Law Firm

Jul 23, 2025, 11:50 AM EDT - 4 months ago

RXSIGHT, INC. (NASDAQ: RXST) INVESTOR ALERT Investors With Large Losses in RxSight Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

Jul 21, 2025, 1:09 PM EDT - 4 months ago

RxSight, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – RXST

Jul 21, 2025, 10:21 AM EDT - 4 months ago

RXST Investors Have Opportunity to Join RxSight, Inc. Fraud Investigation with the Schall Law Firm

Jul 20, 2025, 7:08 AM EDT - 4 months ago

RXST SECURITIES NEWS: Did RxSight, Inc. (NASDAQ:RXST) Commit Securities Fraud? Contact BFA Law about its Investigation into the Company

Bullishcatalyst Nov. 13 at 8:15 PM

$RXST run from this turd

0 · Reply

BillionerOfKing Nov. 13 at 5:31 AM

0 · Reply

nathan_ross88 Nov. 12 at 11:41 AM

$RXST medtech growth. Over base top, +7–10% room. Watch revenue cadence commentary

0 · Reply

Vaprtrl Nov. 10 at 7:06 PM

$RXST I smell $12 coming soon

0 · Reply

RocketThief Nov. 7 at 3:26 PM

$RXST that report was solid. Will be happy/greedy if the opportunity to buy $7S comes again

0 · Reply

Vaprtrl Nov. 7 at 6:44 AM

$RXST let’s fill these gaps!

0 · Reply

JarvisFlow Nov. 6 at 10:03 PM

JP Morgan has adjusted their stance on RxSight ( $RXST ), setting the rating to Underweight with a target price of 8 → 9.

0 · Reply

BryGuy29 Nov. 6 at 6:41 PM

$RXST Just sell the company already….. we all know it’s bound to happen.

0 · Reply

JarvisFlow Nov. 6 at 3:43 PM

Wells Fargo updates rating for RxSight ( $RXST ) to Equal-Weight, target set at 9 → 10.

0 · Reply

No_Body_Knows Nov. 6 at 1:51 PM

$RXST

1 · Reply

Siesta94 Nov. 6 at 12:26 PM

$RXST Time to squeeze the Shorties 4,25 Mio. Shares , 4,5 days to cover , 11,5 % of float Next stop 20

0 · Reply

JarvisFlow Nov. 6 at 10:12 AM

Needham updates rating for RxSight ( $RXST ) to Buy, target set at 11 → 12.

0 · Reply

PaulLaurent Nov. 6 at 4:55 AM

🚀📈 Top Gainers 📈🚀AH $FRGE $LZ $SKYT $RXST $MTC

0 · Reply

Vaprtrl Nov. 6 at 12:14 AM

$RXST got some nice gaps to fill here..

0 · Reply

d_risk Nov. 5 at 9:32 PM

$RXST - RxSight Inc. Common Stock - 10Q - Updated Risk Factors RXST’s latest 10-Q sharpens focus on sales force and brand growth risks, adds new sections on intellectual property, regulatory hurdles (including post-Chevron FDA litigation risk), and ongoing litigation; expands detail on commercialization, compliance, international laws, stock volatility, and internal controls, while streamlining duplicate entries. #Healthcare #SalesGrowth #Litigation #RegulatoryRisk #IntellectualProperty 🟢 Added 🟠 Removed https://d-risk.ai/RXST/10-Q/2025-11-05

0 · Reply

elmono Nov. 5 at 8:00 PM

$RXST Why the fuck is this so brutally shorted today? Bad stuff coming tomorrow?

1 · Reply

BryGuy29 Nov. 5 at 6:20 PM

$RXST expectations is super low. This might be a great buy right here.

1 · Reply

BryGuy29 Nov. 5 at 5:54 PM

$RXST whose buying before earnings ? 😬

0 · Reply

CH_Expat Oct. 21 at 3:11 PM

$RXST I take the 7% here. Waiting for 6ish to buy back in. Cyclical stuff here and undervalued without a doubt, just like other stuff better right now.

0 · Reply

RocketThief Oct. 16 at 4:51 PM

$RXST I guess on a day like today that massive pile of cash doesn’t look too bad

0 · Reply

elmono Oct. 13 at 2:03 PM

$RXST cockroaches who dropped this …will pay. This will come roaring back, count on it

0 · Reply

CH_Expat Oct. 12 at 1:48 PM

If you are interested in fully bombed out Medtech, here are some tickers: $INSP $RXST $LUNG.

1 · Reply

Market Cap	400.07M
Revenue (ttm)	139.93M
Net Income (ttm)	-27.46M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-19.62%
Debt to Equity Ratio	0.00

Volume	610,500
Avg Vol	766,276
Day's Range	N/A - N/A
Shares Out	41.12M
Stochastic %K	63%
Beta	1.16
Analysts	Hold
Price Target	$9.67